08 Apr ACTIV-2 Study
The ACTIV-2 trial is an adaptive design study that prioritizes the development of promising new therapeutics to expand our treatments of COVID-19. We're testing different medicines to see if they're safe and can help adults recover more quickly.
Teams of dedicated researchers want to ensure that these new medicines are 1) safe 2) helps reduce the duration and severity of COVID-19 symptoms 3) can get rid of the virus and 4) can keep people from getting sicker and/or going to the hospital. Another important goal of this study considers treatment access, especially agents that can administered more easily in a diversity of settings and communities.
We're testing multiple agents under the ACTIV-2 master protocol – these treatments are assigned through randomization and compared to a placebo control group. There are different types of agents that fall within two categories: 1) treatments that do not require an intravenous infusion (e.g. oral medication) and 2) agents that are infused. Everyone receives the same level of high quality care and safety monitoring to ensure a smooth recovery.
Learn more at our Facebook page or study website at http://www.riseabovecovid.org/
If you're interested in helping us "Rise Above COVID" by participating in treatment research, we're looking for folks who satisfy the following:
– Individuals 18 years of age or older.
– If you've recently tested positive for SARS-CoV-2 within 10 days.
– If your symptoms began within 8 days and you're still experiencing symptoms at home.
Both vaccines and treatment are important tools to curb the spread of the virus in our communities. Call to learn more!
ACTIV-2 Researcher @ UW ACTU
Additional Study Details
Full Study Title
ACTIV-2 An Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)
Dr. Rachel Bender-Ignacio
Accepts Healthy Volunteers?
ACTU/Madison Clinic at Harborview Medical Center
325 9th Ave 2WC
Seattle, Washington 98104